BioLineRx and Hemispherian Announce New Preclinical Data Demonstrating Strong Synergistic Effect between GLIX1 and PARP Inhibitor in a Patient-Derived Ovarian Cancer Xenograft Model
Go back to BioLineRx and Hemispherian Announce New Preclinical Data Demonstrating Strong Synergistic Effect between GLIX1 and PARP Inhibitor in a Patient-Derived Ovarian Cancer Xenograft Model| BIOLINE RX SP ADR (NASDAQ: BLRX) | Delayed: 2.43 -0.05 (2.02%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.48 | 52 Week High | $1.63 | |||
| Open | $2.48 | 52 Week Low | $0.71 | |||
| Day High | $2.60 | P/E | N/A | |||
| Day Low | $2.42 | EPS | $0.00 | |||
| Volume | 10,354 | |||||
| BIOLINE RX SP ADR (NASDAQ: BLRX) | Delayed: 2.43 -0.05 (2.02%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.48 | 52 Week High | $1.63 | |||
| Open | $2.48 | 52 Week Low | $0.71 | |||
| Day High | $2.60 | P/E | N/A | |||
| Day Low | $2.42 | EPS | $0.00 | |||
| Volume | 10,354 | |||||
